CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) ± 5-fluorouracil and leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy.
Authors
Chen, LWang-Gillam, A
Shan, Y
Macarulla, T
Blanc, J
Hubner, Richard A
Chiu, C
Schwartsmann, G
Siveke, J
Pipas J
Belanger, B
de Jong, F
Mamlouk, K
Von Hoff, D
Affiliation
National Health Research Institutes (NHRI) – National Institute of Cancer Research, Tainan, TaiwanIssue Date
2017-06
Metadata
Show full item recordCitation
CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) ± 5-fluorouracil and leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy 2017, 28 (suppl_3) Ann OncolJournal
Annals of OncologyDOI
10.1093/annonc/mdx263.016Type
Meetings and ProceedingsLanguage
enISSN
0923-75341569-8041
ae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdx263.016